Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Pharmacokinetics in Pediatric Patients: Drug Metabolism

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sponsor Initiated Requests to Delay Pediatric Postmarketing Studies.

Pharmaceutical medicine·2026

Same author

Effect of Incentivizing Pediatric Studies on the Development of Pediatric-Friendly Formulations.

The AAPS journal·2026

Same author

PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation Development.

The AAPS journal·2026

Same author

Paediatric developmental safety and the ICH E11A extrapolation of safety.

British journal of clinical pharmacology·2025

Same author

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

Clinical pharmacology and therapeutics·2025

Same author

Pediatric Hepatic Impairment Dosing in FDA Approvals Between 2002 and 2024.

Clinical pharmacology and therapeutics·2025

Search research articles

Related Experiment Video

Updated: Oct 31, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Progress in Drug Development-Pediatric Dose Selection: Workshop Summary.

Jian Wang¹, John N van den Anker², Gilbert J Burckart³

¹Office of Specialty Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Journal of Clinical Pharmacology

|June 29, 2021

Summary

This article summarizes a workshop on pediatric dose selection, focusing on optimizing drug development for children. Key presentations addressed challenges and strategies for safe and effective pediatric therapeutics.

Keywords:

PBPK allometry drug development pediatrics (ped)special populations

More Related Videos

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Published on: June 11, 2017

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

Related Experiment Videos

Last Updated: Oct 31, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Published on: June 11, 2017

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Making MR Imaging Child's Play - Pediatric Neuroimaging Protocol, Guidelines and Procedure

Published on: July 30, 2009

Area of Science:

Pharmacology and Therapeutics
Regulatory Science
Pediatric Medicine

Background:

Pediatric drug development presents unique challenges in dose selection.
Ensuring safe and effective medication for children requires specialized approaches.
Regulatory frameworks guide pediatric therapeutic innovation.

Purpose of the Study:

To summarize key presentations from the "Pediatric Dose Selection" workshop.
To highlight advancements and considerations in pediatric drug development.
To provide insights into regulatory science for pediatric therapeutics.

Main Methods:

Review of presentations from the October 2020 workshop.
Synthesis of information on pediatric dose selection strategies.
Contextualization within the framework of pediatric drug development.

Main Results:

The workshop convened experts to discuss pediatric dose selection.
Presentations covered various aspects of optimizing drug dosage for pediatric populations.
The event fostered discussion on regulatory and scientific considerations.

Conclusions:

Effective pediatric dose selection is crucial for drug safety and efficacy.
Collaboration between regulatory bodies and academic institutions advances pediatric therapeutics.
Continued focus on specialized pediatric drug development is essential.